Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ETCompany ParticipantsConstantin Fest - Head of Investor ...

The German life-science and chemicals company attributed earnings growth to a recovery of its life-science segment, cost discipline and lower spending on research and development following the ...

Its health care business showed good profitability thanks to multiple sclerosis drug Mavenclad and cancer drug Erbitux, as ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

Those two drugs are billed as Merck 'wave 2' medicines, building on a first wave of recent launches, including PD-1 inhibitor Bavencio (avelumab), Mavenclad (cladribine) for MS and lung cancer ...

There’s no news yet on its US list price. Along with other S1P drugs, it will also have to compete with Merck KGaA’s Mavenclad (cladribine), which has a difference mechanism of action but was ...

There is growing evidence that Autologous Haematopoietic Stem Cell Transplantation (aHSCT or HSCT) is an effective treatment for relapsing remitting MS. However, there has not yet been a direct ...

Medications are the mainstay of treatment for multiple sclerosis (MS). Many of them are used to block the immune system's attack on the nerves and slow or prevent progression and relapses (flare-ups) ...